ADAM10 and central nervous system cancer: Subsequent studies identified that NLGN3 is cleaved by ADAM10 and secreted into the TME 0and ADAM10 inhibitors were found to inhibit the release of NLGN3 and consequently prevent growth of patient-derived orthotopic xenograft.95 In addition, Nlgn3 knockout mice are unable to harbor patient-derived orthotopic xenografts of several molecular subtypes of high-grade glioma and show durable inhibition of glioma growth despite minimal impact on neurologic function (attributed to the increased compensatory expression of other neuroligins in normal synapses).